Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: An European Organisation for Research and Treatment of Cancer study

Bone Marrow Transplantation

Volumn 45, Issue 7, 2010, Pages 1227-1233

  Herbrecht, R ^a   Maertens, J ^b   Baila, L ^c   Aoun, M ^d   Heinz, W ^e   Martino, R ^f   Schwartz, S ^g   Ullmann, A J ^h   Meert, L ^c   Paesmans, M ^c   Marchetti, O ⁱ   Akan, H ^j   Ameye, L ^d   Shivaprakash, M ^k   Viscoli, C ^l  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c EORTC DATA CENTER   (Belgium)

^d JULES BORDET INSTITUTE   (Belgium)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h JOHANNES GUTENBERG UNIVERSITY   (Germany)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j ANKARA UNIVERSITY   (Turkey)

^k MERCK RESEARCH LABORATORIES   (United States)

^l UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CASPOFUNGIN; RAPAMYCIN; STEROID; ANTIFUNGAL AGENT; ECHINOCANDIN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPOKALEMIA; INVASIVE ASPERGILLOSIS; LOADING DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; LYMPHOMA; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; ADVERSE DRUG REACTION; ALLOTRANSPLANTATION; ASPERGILLOSIS; DRUG COMBINATION; EUROPE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; TOXICITY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG THERAPY, COMBINATION; DRUG TOXICITY; ECHINOCANDINS; EUROPE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS;

EID: 77955012411     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.334     Document Type: Article

References (26)

1. Marr K, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
2. Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol 2002; 81: 233-243.
3. Ribaud P, Chastang C, Latgé JP, Baffroy-Lafitte L, Parquet N, Devergie A et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322-330. (Pubitemid 29241222)
4. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Amé S, Fohrer C et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47: 1176-1184.
5. Marr K, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917. (Pubitemid 34229758)
6. Pagano L, Caira M, Nosari A, Van Lint MT, Candoni A, Offidani M. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45: 1161-1170.
7. Cannon J, Garey KW, Danziper LH. A prospective and retrospective analysis of the nephtrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 2001; 21: 1107-1114.
8. Cornely O, Lasso M, Betts R, Klimko N, Vazquez J, Dobb G et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrobial Chemother 2007; 60: 363-369.
9. Ullmann A. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin 2003; 19: 263-271.
10. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571.
11. Kartsonis N, Nielsen J, Douglas CM. Caspofungin: the first in a new class of antifungal agents. Drug Resist Update 2003; 6: 197-218.
12. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
13. Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A et al. Caspofungin as first-line therapy of invasive aspergillosis in haematological patients: a study of the EORTC Infectious Diseases Group. J Antimicrob 2009; 64: 1274-1281.
14. Viscoli C, Machetti M, Cappellano P, Bucci B, Bruzzi P, Van Lint MT et al. False-positive galactomannan platelia Apergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913-916.
15. Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20: 1898-1906.
16. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415. (Pubitemid 34851833)
17. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041-1050.
18. Cornely O, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis 2007; 44: 1289-1297.
19. Cornely O, Maertens J, Ullmann AJ, Heussel CP, Herbrecht R. Reply to denning. Clin Infect Dis 2007; 45: 1108-1109.
20. Segal B, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clin Infect Dis 2008; 47: 674-683.
21. Wingard J, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 2008; 112: 2309-2312.
22. Walsh T, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.
23. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
24. Wingard J, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, L Amph/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000; 31: 1155-1163.
25. Nivoix Y, Levêque D, Herbrecht R, Koffel JC, Beretz L, Ubeaud-Sequier G. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008; 47: 77-792.
26. Morrissey C, Slavin MA, O'Reilly MA, Daffy JR, Seymour JF, Schwarer AP et al. Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A. Mycoses 2007; 50(Suppl 1): 24-37.